Table 4.
Demographic, clinical, and blood test characteristics of the global population and after sorting for survival.
| Global Cohort (n = 60) |
Survivors (n = 37) |
Non-Survivors (n = 23) |
p-Value | |
|---|---|---|---|---|
| Age, years | 68.0 (62.0–73.5) | 66.0 (62.0–73.3) | 70.0 (61.5–74.5) | 0.37 |
| Gender (M/F) | 44/16 | 27/10 | 17/6 | 0.94 |
| Smoking status, n (no/former/yes) | 3/43/11 | 3/25/7 | 0/18/4 | 0.35 |
| Histological type, n (ADK/SQ) | 51/9 | 33/4 | 18/5 | 0.25 |
| PD-L1, n (1–49%/<1%) | 29/29 | 18/17 | 11/12 | 0.79 |
| Stage T, n (T1/T2/T3/T4) | 4/2/3/51 | 4/2/2/29 | 0/0/1/22 | 0.23 |
| Stage N, n (N0/N1/N2/N3) | 3/8/10/38 | 3/7/5/21 | 0/1/5/17 | 0.15 |
| Hb (g/dL) | 12.3 ± 1.7 | 12.6 ± 1.8 | 12.2 ± 1.7 | 0.43 |
| RDW, (%) | 14.6 (13.6–15.7) | 14.4 (13.3–15.8) | 14.8 (14.1–15.6) | 0.51 |
| WBC, n (×109 L) | 8.94 (7.41–11.53) | 8.26 (6.36–9.92) | 9.69 (7.97–14.03) | 0.026 |
| Neutrophils, n (×109 L) | 6.00 (4.10–7.81) | 5.30 (3.48–7.03) | 7.00 (6.00–11.95) | 0.001 |
| Lymphocytes, n (×109 L) | 1.70 (1.30–2.23) | 1.80 (1.40–2.50) | 1.50 (1.13–2.00) | 0.14 |
| Monocytes, n (×109 L) | 0.60 (0.50–0.80) | 0.60 (0.50–0.80) | 0.80 (0.50–0.80) | 0.32 |
| Platelets, n (×109 L) | 287 (252–353) | 270 (238–336) | 314 (281–407) | 0.052 |
| NLR | 3.45 (2.20–5.42) | 2.94 (1.92–3.88) | 4.56 (3.07–9.49) | 0.012 |
| NMR | 9.60 (7.60–11.75) | 9.00 (7.08–11.05) | 10.40 (8.80–18.18) | 0.007 |
| MLR | 0.34 (0.24–0.54) | 0.33 (0.24–0.41) | 0.43 (0.24–0.58) | 0.16 |
| PLR | 169 (119–246) | 136 (107–201) | 220 (145–273) | 0.016 |
| SII | 985 (626–1709) | 849 (488–1081) | 1493 (1000–2578) | 0.0004 |
| AISI | 594 (279–1168) | 351 (256–794) | 1016 (470–1836) | 0.006 |
ADK: adenocarcinoma; AISI: aggregate index of systemic inflammation; F: female; Hb: hemoglobin; M: male; MLR: monocyte to lymphocyte ratio; NLR: neutrophil to lymphocyte ratio; NMR: neutrophil to monocyte ratio; PD-L1: programmed death ligand 1; RDW: red cell distribution width; SII: systemic inflammation index; SQ: squamous cell cancer; WBC: white blood cells.